Image for illustrative purposes only. Not a real photo.

Kailera completes ribupatide Phase 3 enrollment

Escrito por Liezl GambePublicado Sep 30, 2026, 2:49 PM

Kailera Therapeutics (NASDAQ:KLRA) announced completion of enrollment across three global Phase 3 trials evaluating investigational once-weekly ribupatide injection in people with obesity or overweight.

4 months ago

Kailera reports 11.1% weight loss data

Kailera Therapeutics (NASDAQ:KLRA) reported topline data from two Jiangsu Hengrui Pharmaceuticals Phase 3 trials of oral GLP-1 agonist HRS-7535/KAI-7535 in China, including mean weight loss of up to 11.1%.

Mais formas de descobrir

Ver notícias de United States Descubra sinais de NYSE Ver todas as ações de NYSE Ver todos os ETFs de NYSE Explorar empresas de United States Encontre o índice NYSE ideal

Notícias relacionadas

Kailera reports 11.1% weight loss data

Mais formas de descobrir

Notícias relacionadas

Kailera reports 11.1% weight loss data

Ativos relacionados a notícia